XORTX Therapeutics Appoints Altasciences as CRO for Clinical Study
Dr. Allen Davidoff, President and CEO stated, XORTX is pleased to be starting work with Altasciences as we initiate the characterization of our novel, proprietary formulations of xanthine oxidase inhibitors.
- Dr. Allen Davidoff, President and CEO stated, XORTX is pleased to be starting work with Altasciences as we initiate the characterization of our novel, proprietary formulations of xanthine oxidase inhibitors.
- XORTX is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid.
- At XORTX Therapeutics, we are dedicated to developing medications to improve the quality of life and future health of patients.
- Altasciences integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring and data management, all customizable to specific sponsor requirement.